Medtronic’s $382 million antitrust verdict is a reminder that “how you sell” can become as material as what you sell. A federal jury in Santa Ana, California, found on February 5, 2026 that Medtronic...
Medtronic’s $382 million antitrust verdict is a reminder that “how you sell” can become as material as what you sell. A federal jury in Santa Ana, California, found on February 5, 2026 that Medtronic unlawfully monopolized the U.S. market for certain blood-vessel sealing surgical devices and awarded Applied Medical Resources $381.7 million in damages. [1] Applied Medical sells a competing device called Voyant; Medtronic’s product is LigaSure, used to cut tissue and seal blood vessels during surgery. [1] The conduct at issue wasn’t a single price cut or an aggressive sales quarter. Applied argued that Medtronic used a playbook of below-cost pricing for LigaSure and “bundling” it with other products to make it economically painful for hospitals to buy a rival’s tools. [1] The dispute also turned on contracting: Applied challenged Medtronic’s hospital agreements, alleging they functioned like exclusive-dealing arrangements by threatening the loss of discounts on unrelated products if customers shifted volume to competitors. [1] Medtronic denied the allegations and said it plans to appeal. In a statement reported by Reuters, the company argued surgeons choose LigaSure because it outperforms Voyant. [1] Medtronic also maintained at trial that its “commitment” contracts are not exclusive, are common in the medical device industry, and that Applied failed to show hospitals were prevented from buying other devices. [1] Two next steps matter as much as the headline number. First, the damages may not be the final figure. Applied’s counsel told Reuters that the verdict could allow the judge to triple damages under federal antitrust law, though that would depend on post-trial motions and rulings. [1] Second, Applied has said it intends to seek injunctive relief to stop Medtronic from enforcing what it describes as restrictive contract terms—remedies that, if granted, can reshape day-to-day commercial behavior in ways a one-time check cannot. [2] From a business perspective, this case is about incentives. Large device companies love “portfolio economics”: once you have a broad catalog, you can offer hospitals simplified purchasing, predictable pricing, and volume discounts across categories. That can be efficient for customers—until it crosses the line into making it artificially hard for a rival to compete in a single category. The jury appears to have accepted Applied’s argument that Medtronic’s discounts and bundles weren’t merely tough competition; they were exclusionary. [1] For investors, the key question is less “Can Medtronic afford it?” and more “Could this change the durability of a high-margin franchise?” Medtronic’s scale means a $382 million verdict is painful but not existential. The bigger downside risk is operational: if a court ultimately restricts the contracting tactics that helped LigaSure maintain share, pricing could become more transparent, discounting could spread, and rivals could win accounts that previously felt “locked.” That...Value Investing Hub
Professional-grade stock analysis platform for value investors. Access DCF calculators, stock screeners, market insights, and educational resources.